Gruppo Italiano Malattie EMatologiche dell'Adulto: all 134 studies
Page 1 of 2. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.
- Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory PracticeNot yet recruitingNCT07867704Not applicable
- Real World Assessment of Venous Thromboembolic Risk in Hospitalized Patients With Acute LeukemiaNot yet recruitingNCT07831668
- Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent LinesNot yet recruitingNCT07640750
- CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic LeukemiaNot yet recruitingNCT07623655
- Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in ItalyNot yet recruitingNCT07564128
- Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-worldNot yet recruitingNCT07356960
- Momelotinib Effectiveness in MyelofibrosisNot yet recruitingNCT07249606
- Identification of BCR::ABL1 Mutations by Digital PCR in CMLNot yet recruitingNCT07158294Not applicable
- Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTionsRecruitingNCT07080970
- Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM PatientsRecruitingNCT06933277
- Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple MyelomaNot yet recruitingNCT06880601Phase 2
- Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
- HRQoL and Financial Toxicity in Patients With VEXAS SyndromeRecruitingNCT06657846
- Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)RecruitingNCT06513273
- Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010Not yet recruitingNCT06466824
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingNCT06409936Phase 2
- Biological and Clinical Efficacy of Shingrix in Patients With CLLNot yet recruitingNCT06364033Not applicable
- Real-world Ruxolitinib Experience in PVNot yet recruitingNCT06251102
- Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and VenetoclaxNot yet recruitingNCT06090786Not applicable
- Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease ProgressionNot yet recruitingNCT06084923
- Real-World Mapping Antithrombotic Regimens in MM Patients on TreatmentRecruitingNCT06028087
- Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INORecruitingNCT06025682
- Real World Evidence of Fedratinib Effectiveness in MFRecruitingNCT05883904
- Novel Approaches to Target MECOM/EVI1 in AMLRecruitingNCT05839392Not applicable
- Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.RecruitingNCT05803395
- Biologic Characterization of Patients With ITPRecruitingNCT05694325Not applicable
- Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
- Study on the Diagnosis and Management of CLL in Italy by GIMEMARecruitingNCT04867915
- LCH in Adults: a Collaborative, Prospective-retrospective, Observational StudyRecruitingNCT04627090
- Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS PatientsRecruitingNCT04587856Not applicable
- Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALLRecruitingNCT04582487Not applicable
- Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid NeoplasmsRecruitingNCT04460950
- Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)RecruitingNCT04184505Phase 3
- AML Patients Bearing FLT3 Mutations Based on Peripheral Blast ClearanceRecruitingNCT04174612Phase 3
- Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLRecruitingNCT04168502Phase 3
- Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) AdultsCompletedNCT01462253Phase 2Results posted
- Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01403246Phase 1/2Results posted
- GIMEMA CLL0809 Study (BendOfa)CompletedNCT01244451Phase 2Results posted
- Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00775593Phase 2Results posted
- Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to TherapyCompletedNCT00727415Phase 1/2Results posted
- Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous LeukemiaCompletedNCT00466726Phase 2Results posted
- Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic LeukemiaCompletedNCT00462332Phase 2Results posted
- Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic LeukemiaCompletedNCT00458848Phase 2Results posted
- PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDSCompletedNCT00439673Phase 2Results posted
- Treatment of Adult Ph+ LAL With BMS-354825CompletedNCT00391989Phase 2Results posted
- Daratumumab in VHR T-ALL Treated According to the ALL National Treatment ProgramActive, not recruitingNCT06253637Phase 2
- Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real LifeCompletedNCT06026644
- Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL StudyCompletedNCT05927558
- Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITPCompletedNCT05613296
- Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLLActive, not recruitingNCT05478512Phase 2
- Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia PatientsActive, not recruitingNCT05306301Phase 2
- Use of nMoABs for the Treatment of COVID-19 in Patients With HM.CompletedNCT04932967
- Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid LeukemiaStatus unknownNCT04867928Phase 2
- Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
- Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITPStatus unknownNCT04735588
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
- Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL PatientsStatus unknownNCT04640909Not applicable
- Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96CompletedNCT04589728
- An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic MalignanciesStatus unknownNCT04581187
- Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological RelapseActive, not recruitingNCT04475731Phase 2
- Role of Adrenomedullin in Leukemic Endosteal/Vascular NichesActive, not recruitingNCT04460963Not applicable
- Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).Active, not recruitingNCT04378855
- Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid LeukemiaTerminatedNCT04342962Phase 2
- Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in ItalyActive, not recruitingNCT04282811
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- Long-term Outcomes for Acute Myeloid Leukemia PatientsStatus unknownNCT03755856
- Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic LeukemiaStatus unknownNCT03751917
- Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT03668392Phase 2
- Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT03610438Phase 2
- Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC StudyCompletedNCT03545035
- The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With IbrutinibCompletedNCT03528941
- Investigation on a Dynamic Cohort of Italian Patients With Active ITPStatus unknownNCT03465020
- Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
- Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid LeukemiaCompletedNCT03455504Phase 2
- Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)TerminatedNCT03410407
- Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaCompletedNCT03367299Phase 2
- Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus unknownNCT03318770
- Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT03190525
- Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard ChemotherapyStatus unknownNCT03096496
- Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid LeukemiaStatus unknownNCT03075969
- Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid LeukemiaCompletedNCT02986620
- Bosutinib in Elderly Chronic Myeloid LeukemiaCompletedNCT02810990Phase 2
- D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02744768Phase 2
- Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
- Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient ProgramCompletedNCT02582320
- Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic LeukemiaCompletedNCT02491398
- Retrospective Evaluation of CML Patients in the National Compassionate ProgramTerminatedNCT02448095
- Eltrombopag in Second Line Adult Primary Immune ThrombosytopeniaCompletedNCT02402998Phase 2
- Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
- Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
- Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune ThrombocytopeniaCompletedNCT02298075
- Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
- Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT02185781Phase 1
- LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia PatientsStatus unknownNCT02164903
- MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted MethotrexateCompletedNCT02067143Phase 2
- TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.CompletedNCT02063763
- Occupational Status and Hematological DiseaseCompletedNCT02057185
- Observational Evaluation of Infective Risk in Myelodysplastic Syndrome PatientsCompletedNCT01951430
- Long-Term Quality of Life in Patients With Acute Promyelocytic LeukemiaCompletedNCT01910623
- Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL PatientsStatus unknownNCT01862445
← Gruppo Italiano Malattie EMatologiche dell'Adulto overview and focus areas